Posttransplant Lymphoproliferative Disorder in Pediatric Solid-Organ Transplant Recipients: A 7-Year Single-Center Analysis.
Early diagnosis of posttransplant lymphoproliferative disorder is important, and rituximab with immunosuppression reduction is effective to achieve complete remission, particularly in early polymorphic cases. Despite challenges, all patients achieved remission, signaling improved outcomes in pediatric posttransplant lymphoproliferative disorder. Active monitoring of Epstein?Barr virus infection may further reduce posttransplant lymphoproliferative disorder complications in pediatric solid-organ transplant; hence, early diagnosis is crucial.
Authors
- Lale Olcay (ORCID: https://orcid.org/0000-0002-5684-0581)
- B. Handan Özdemir (ORCID: https://orcid.org/0000-0002-7528-3557)
- Oya Balcı Sezer (ORCID: https://orcid.org/0000-0002-8402-8208)
- Figen Özçay (ORCID: https://orcid.org/0000-0002-5214-516X)
- Emre Karakaya (ORCID: https://orcid.org/0000-0002-4879-7974)
- Esra Baskın (ORCID: https://orcid.org/0000-0003-4361-8508)
- Fatma Burcu Belen (ORCID: https://orcid.org/0000-0002-9278-6703)
- Adem Şafak (ORCID: https://orcid.org/0000-0003-2817-1920)
- Pamir Işık (ORCID: https://orcid.org/0000-0002-9618-5008)
- Mehmet Haberal (ORCID: https://orcid.org/0000-0002-3462-7632)
- Cavitcan Müezzinoğlu
Institutions
- Başkent University (TR)
Publication Details
- Journal
- Experimental and Clinical Transplantation
- Published
- 2024-10-01
- DOI
- https://doi.org/10.6002/ect.pedsymp2024.o5
- Citations
- 1
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article